Novonesis and Novo Nordisk will explore new solutions to improve metabolic health
MWN-AI** Summary
Novonesis and Novo Nordisk have announced a groundbreaking research collaboration aimed at enhancing metabolic health through the exploration of the gut microbiome. This partnership, set to begin in Copenhagen on September 8, 2025, will delve into how the microorganisms residing in the human gut influence metabolic health—a field that has gained significant traction in recent years. By focusing on the gut microbiome, the collaboration seeks to develop and test synbiotic food supplements, which combine probiotics (beneficial bacteria) and prebiotics (substances that feed these bacteria) to improve health outcomes related to metabolic conditions, such as blood glucose and cholesterol levels.
Notable figures leading the initiative include Henrik Joerck Nielsen, Executive Vice President of Human Health Biosolutions & Strategy at Novonesis, who emphasizes the importance of understanding the microbiome's role in overall health and well-being. Similarly, Professor Nadeem Sarwar of Novo Nordisk highlights the complexity of obesity as a chronic disease influenced by various factors, including genetics, hormones, and gut health. This collaboration aligns with Novo Nordisk’s mission to combat the global obesity epidemic through innovative, science-driven prevention strategies.
As obesity is linked to over 200 health complications, including type 2 diabetes and cardiovascular diseases, the partnership aims to develop novel biomarkers to monitor and predict health trajectories and measure the effectiveness of microbiome-based interventions. Through their combined expertise in microbiology and chronic disease management, Novonesis and Novo Nordisk aspire to create impactful biosolutions that promote long-term health and well-being across different life stages, leveraging their resources to address one of the pressing health challenges of the modern era.
MWN-AI** Analysis
The recent collaboration between Novonesis and Novo Nordisk marks a significant stride in the exploration of metabolic health, particularly through the lens of the gut microbiome. This partnership not only underscores the increasing recognition of the microbiome's role in human health but also positions both companies strategically within a burgeoning industry focused on metabolic disease management, particularly obesity.
As both entities strive to develop synbiotic food supplements, they could potentially tap into the growing consumer demand for preventive health solutions. With obesity acknowledged as a complex disease leading to multiple health complications, the need for innovative and scientifically-backed interventions is critical. The application of probiotics and prebiotics presents a unique opportunity to attract health-conscious consumers seeking holistic health improvements.
From an investment perspective, this collaboration signals an expansion of Novo Nordisk and Novonesis' capabilities, potentially leading to lucrative product offerings. Novo Nordisk's established reputation in chronic disease management, combined with Novonesis's biotechnological innovations, could yield scalable solutions with broad market applicability. Consequently, investors might find value in these companies as they venture into relatively untapped areas of health maintenance, targeting a demographic increasingly motivated by preventive health measures.
Moreover, the focus on predictive analytics through novel biomarkers could enhance personalized healthcare offerings, garnering interest from both healthcare providers and patients. This direction not only aligns with global health trends but also indicates a proactive approach to managing obesity and its associated risks.
In summary, investors should closely monitor Novonesis and Novo Nordisk's developments, as their joint initiative could redefine strategies for metabolic health improvement. This partnership may represent a pivotal moment for advancing solutions that resonate with evolving consumer priorities around wellness and disease prevention.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people.
COPENHAGEN, Denmark – September 8, 2025. Novonesis and Novo Nordisk has entered a research partnership to explore the role of the gut microbiome in the maintenance of metabolic health. The gut microbiome is the collection of microorganisms, such as bacteria, fungi, and viruses, that naturally live in the human gut. The science surrounding the microbiome, and how it contributes to human health in many ways, has grown tremendously over the last years 1 .
Novonesis and Novo Nordisk will work closely to explore solutions that seek to preserve and optimize metabolic health and improve people’s well-being mediated through the gut microbiome. Synbiotic food supplements, composed of probiotics and prebiotics, will be developed and tested for their ability to affect health parameters linked to metabolic health such as blood glucose and cholesterol levels. Probiotics are living microorganisms, while prebiotics are the “fuel” that helps sustain these beneficial microorganisms. 2
The partnership will investigate how the gut microbiome may be used to monitor and predict metabolic and overall health trajectories in individuals. Additionally, it will explore novel biomarkers with the aim of measuring the effectiveness of gut microbiome solutions.
“At Novonesis, we are committed to advancing our understanding of the human microbiome and the crucial role it plays in digestion, immunity, mood, well-being, and much more. This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome’s role in maintaining metabolic health and to identify innovative products that support it. Together, we will conduct research on the gut microbiome for predictive purposes and strive to create impactful biosolutions that enhance health and well-being throughout life stages”, says Henrik Joerck Nielsen, Executive Vice President, Human Health Biosolutions & Strategy.
Obesity is recognized as a chronic, progressive disease by the World Health Organization (WHO). 3 It is a multifactorial disease that is associated with more than 200 possible health complications, including type 2 diabetes and cardiovascular disease. 4
“Obesity is a complex disease driven by multiple factors, including our hormones and genetics, and we are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity, 5 ” says Professor Nadeem Sarwar, Corporate Vice President and Head of the Transformational Prevention Unit in Obesity at Novo Nordisk.
“Prevention is an integral part of Novo Nordisk’s sustainable and holistic approach to stop the global rise of obesity. The Transformational Prevention Unit’s mission is to deliver science-based and scalable commercial solutions to predict and pre-empt obesity and its consequences for people at greatest risk. We can’t do this alone – building novel, multi-sector partnerships is crucial to deliver impactful solutions. We are excited to work with Novonesis to explore strategies for promoting long-term health that may support us on our mission.”
About Novonesis
Novonesis is leading the era of biosolutions. By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube .
| Media Relations - Novonesis | Media Relations – Novo Nordisk | |
| Jens Gamborg Interim Head of External Communication Phone: +45 30 77 71 82 jgam @novonesis.com | Martin Havtorn Petersen Global Media & Stakeholder Comms Lead Phone: +45 30 75 52 46 mhpz@novonordisk.com |
1 Marco ML. Defining how microorganisms benefit human health. Microbial Biotechnology (2020). Available at: https://doi.org/10.1111/1751-7915.13685 .
2 Science Direct, Chapter 12 – The Role of Prebiotics in Disease Prevention and Health Promotion (2019). Available at: https://doi.org/10.1016/B978-0-12-814468-8.00012-0
3 World Health Organization. Obesity and Overweight (2025). Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight .
4 Horn, D.B., Almandoz, J. P., & Look, M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgraduate medicine (2022), 134(4), 359–375.
5 Delzenne, N.M., Bindels, L.B., Neyrinck, A.M. et al. The gut microbiome and dietary fibres: implications in obesity, cardiometabolic diseases and cancer. Nat Rev Microbiol (2024). Available at: https://doi.org/10.1038/s41579-024-01108-z .
FAQ**
How does the partnership between Novonesis AS - Class B NVZMF and Novo Nordisk aim to leverage the gut microbiome in their research to enhance metabolic health solutions?
What specific innovations in synbiotic food supplements are Novonesis AS - Class B NVZMF and Novo Nordisk looking to develop and test in their collaboration?
Can you elaborate on the potential biomarkers that Novonesis AS - Class B NVZMF and Novo Nordisk plan to identify for monitoring gut microbiome effectiveness in metabolic health?
How does the collaboration between Novonesis AS - Class B NVZMF and Novo Nordisk align with Novo Nordisk's mission to address obesity as a complex and chronic disease at a global level?
**MWN-AI FAQ is based on asking OpenAI questions about Novonesis AS - Class B (OTC: NVZMF).
NASDAQ: NVZMF
NVZMF Trading
-2.1% G/L:
$56.14 Last:
144 Volume:
$57.342 Open:
